Market News
Latest news from Stock markets.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - FCX
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Freeport-McMoRan Inc. (NYSE: FCX) between February 15, 2022 and September 24, 2025, both dates inclusive (the "Class Period"), of the important January 12, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Freeport-McMoRan securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYE
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sprouts Farmers Market, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SFM
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities and sellers of put options of Sprouts Farmers Market, Inc. (NASDAQ: SFM) between June 4, 2025 and October 29, 2025, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2026.
...keep reeding on newsfilecorp.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DeFi Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DEFT
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of DeFi Technologies, Inc. (NASDAQ: DEFT) between May 12, 2025 and November 14, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
...keep reeding on newsfilecorp.com
CPTN DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cepton, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CPTN
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of common stock of Cepton, Inc. (NASDAQ: CPTN) between July 29, 2024 and January 6, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased or sold Cepton common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OWL
New York, New York--(Newsfile Corp. - December 7, 2025) - Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Blue Owl Capital Inc. (NYSE: OWL) between February 6, 2025 and November 16, 2025. A class action lawsuit has already been filed.
...keep reeding on newsfilecorp.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Alexandria Real Estate Equities, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARE
New York, New York--(Newsfile Corp. - December 7, 2025) - Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Alexandria Real Estate Equities, Inc. (NYSE: ARE) between January 27, 2025 and October 27, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
...keep reeding on newsfilecorp.com
ROSEN, A LEADING LAW FIRM, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - PRGO
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Perrigo securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
Drilling hits wide zone of mineralisation in new area well outside resource
Intersection of 28.9m at 2.5g/t AuEq just 200m from surface offers potential for additional resource growth; Follow-up drilling to start next week Intersection of 28.9m at 2.5g/t AuEq just 200m from surface offers potential for additional resource growth; Follow-up drilling to start next week
...keep reeding on globenewswire.com
Prediction: This Stock Will Be the Biggest Quantum Computing Winner of 2026
IBM built its first quantum computer in 2019. Unlike most of its quantum peers, IBM earns a profit.
...keep reeding on fool.com
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
...keep reeding on newsfilecorp.com
Here's Why Alphabet Is the Best-Performing "Magnificent Seven" Stock in 2025 (and Why It Has Room to Run in 2026)
In the long run, financial results ultimately prevail over market sentiment. Investor perception toward Alphabet has shifted from pessimistic to realistic.
...keep reeding on fool.com
Gartner Announces Gartner Finance Symposium/Xpo 2026 in Sydney
--(BUSINESS WIRE)--Gartner will explore “Autonomous Finance: Building Resilient, AI-Driven, and Value-Centric Enterprises” during the Gartner Finance Symposium/Xpo.
...keep reeding on businesswire.com
2 High-Yield Dividend ETFs to Buy Today
With the Federal Reserve likely to cut interest rates this week, income investments are essential to helping investors navigate another low-rate era. Two ETFs already offer yields that are 2 to 3 times greater than the S&P 500 average.
...keep reeding on fool.com
Rosen Law Firm Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation - AGL
NEW YORK , Dec. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public.
...keep reeding on prnewswire.com
Can Peloton (PTON) Stock Rebound in 2026?
Peloton continues to explore new initiatives to reduce costs and boost sales, but revenue is still declining. Management is guiding for some improvement in certain areas for 2026.
...keep reeding on fool.com
Why One Hedge Fund Just Put $246 Million Into This Life Sciences Supplier
New York City-based Engine Capital Management bought 14.2 million shares of Avantor in the third quarter. The position value increased by $172 million from the prior period.
...keep reeding on fool.com
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) in patients with large B-cell lymphoma (LBCL), which were presented today in two oral presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. As of the data cutoff date of September 5, 2025, ronde-cel continued to demonstrate robust clinical responses with a manageable safety profile appropriate for outpatient administration. A 93% overall response rate, a 76% complete response rate, and median progression-free survival of 18 months were reported for patients with relapsed and/or refractory (R/R) LBCL in the third- or later-line (3L+) setting. Patients evaluated in the second-line (2L) setting (94% with difficult-to-treat primary refractory disease) achieved an 83% overall response rate and a 61% complete response rate, and 70% of patients with a complete response remained in complete response at 6 months or longer.
...keep reeding on globenewswire.com
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time
...keep reeding on globenewswire.com
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease progression or death in the ITT population, and the treatment-naïve subgroup, which had the longest follow up, showed a 76% reduction These data will be simultaneously published in the Journal of Clinical Oncology and presented at the 2025 American Society of Hematology Annual Meeting and Exposition, as well as featured as part of the meeting's press program INDIANAPOLIS , Dec. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve. Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib (87.0% [95% CI, 82.90-90.44] versus 78.5% [95% CI, 73.73-82.85]; p1% of patients included pneumonia.
...keep reeding on prnewswire.com
MLTX DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTX
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
My Surprising Top "Magnificent Seven" Stock Pick for 2026
Amazon has been a laggard the past few years. However, the company has been doing a lot right behind the scenes, including improving the operational efficiency of its e-commerce operations.
...keep reeding on fool.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - STUB
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub's September 2025 initial public offering (the "IPO"), of the important January 23, 2026 lead plaintiff deadline. SO WHAT: If you purchased StubHub common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
Snowflake Shares Melt. Is It Time to Buy the Stock on the Dip?
The share price of Snowflake dipped despite another strong quarter from the company. The company's growth is driven by the increasing need for AI to have clean, well-organized data.
...keep reeding on fool.com
MRX DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Marex Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - MRX
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
Экспонаты Blokees на выставке CCXP25 в Бразилии -- мировая премьера нового продукта Saint Seiya
/PRNewswire/ -- С 4 по 7 декабря бренд Assembly Character Toys Blokees впервые принял участие в Brazil Comic Con Experience (CCXP). Blokees представили
...keep reeding on prnewswire.com
Blokees auf der CCXP25 in Brasilien: Weltpremiere des neuen Produkts Saint Seiya
/PRNewswire/ -- Vom 4. bis 7. Dezember gab die Assembly Character Toys-Marke Blokees ihr Debüt auf der Brazil Comic Con Experience (CCXP). Blokees präsentierte
...keep reeding on prnewswire.com
Victory Fighting League CEO on Climbing MMA Popularity, TKO Rally
Victory Fighting League CEO, Dan Anderson, talks about his New York-based company and the rise of MMA as a sport. He points to TKO Group (TKO) muscling a strong 2025 rally as a leading signal to consumer interest.
...keep reeding on youtube.com
Why One Fund Dumped Its Entire $15 Million Stake as This Defense Stock Posted $47 Billion in Backlog
New York City-based Engine Capital Management sold 635,255 shares of Amentum worth about $15 million in the third quarter. The move marked an exit for Engine Capital, which reported holding no shares of Amentum as of September 30.
...keep reeding on fool.com
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
...keep reeding on globenewswire.com
S&P 500: Sell Strength (Technical Analysis)
The S&P 500 (SPY) broke its trend channel in November, and the character of the rally has changed. Stock picking is increasingly challenging as leadership fades and some high-growth names may have already topped.
...keep reeding on seekingalpha.com
Netflix co-CEO reportedly discussed Warner Bros. deal with Trump
Will Netflix's $82.7 billion deal to acquire Warner Bros. get approval from federal regulators?
...keep reeding on techcrunch.com
Why One Fund Just Bet $64 Million on a Healthcare Stock Down 63% This Past Year
New York City-based Engine Capital Management initiated a stake in Acadia Healthcare during the third quarter, acquiring nearly 2.6 million shares worth $64 million. The change represents 7.6% of reportable U.S. equity assets under management.
...keep reeding on fool.com
Gentherm Stock Down 60% Since 2022 — But One Hedge Fund Just Bought 431,072 Shares
New York-based Harvey Partners added 431,072 shares of Gentherm in the third quarter. The position value rose by $18.1 million from quarter to quarter.
...keep reeding on fool.com
Where Will Quantum Computing Stock Be in 1 Year?
QCI has established an early mover's advantage in photonic quantum chips. These chips could be easier to scale than electron or ion-driven systems.
...keep reeding on fool.com
SL Green chief expects thriving NYC office market to continue — even under Mamdani
Marc Holliday suggested a willingness to “work with” Mayor-elect Zohran Mamdani and noted that the commercial market thrived throughout previous administrations with different ideologies.
...keep reeding on nypost.com
Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Eagle Pharmaceuticals, Inc. (OTCPK: EGRX) breached their fiduciary duties to shareholders. If you currently own Eagle stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about yo.
...keep reeding on businesswire.com
Better Artificial Intelligence Stock: Palantir Technologies vs. Nvidia
Palantir trades at a stratospheric 109 times revenue while Nvidia's 24 times sales looks almost (almost!) reasonable by comparison.
...keep reeding on fool.com
Evaluating EPD Stock's Actual Performance
Over the past year, Enterprise Products Partners' stock has badly lagged the market. It has also underperformed the S&P 500 over the last three years.
...keep reeding on fool.com
Why One Hedge Fund Has a $28 Million Bet on This Electronics Manufacturing Stock
New York-based Harvey Partners added 41,763 shares of Littelfuse in the third quarter. The position value increased by about $13 million from quarter to quarter.
...keep reeding on fool.com
Replicor publishes data from its compassionate access program in HBV/HDV
/PRNewswire/ - Replicor Inc. announced the publication of data from its first global compassionate access program in the Journal of Hepatology (see here). This
...keep reeding on prnewswire.com
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.
...keep reeding on businesswire.com
1 Growth Stock Down 27% to Buy Right Now
A delay of Rocket Labs' Neutron's launch sparked a 27% selloff, but shares have partially recovered. The third quarter saw record revenue of $155 million, 17 Electron contracts, and a $1 billion backlog.
...keep reeding on fool.com
Why Norwegian Cruise Lines Fell Overboard in November
Norwegian reported earnings during the month, which came in below expectations. Despite the "miss," revenue and margins are going in the right direction.
...keep reeding on fool.com
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
...keep reeding on seekingalpha.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Stride, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - LRN
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Stride, Inc. (NYSE: LRN) between October 22, 2024 and October 28, 2025, both dates inclusive (the "Class Period"), of the important January 12, 2026 lead plaintiff deadline. SO WHAT: If you purchased Stride securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages CarMax, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KMX
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the "Class Period") of the important January 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased CarMax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, A RANKED AND LEADING FIRM, Encourages Primo Brands Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - PRMB, PRMW
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the "Class Period"), of the important January 12, 2026 lead plaintiff deadline. SO WHAT: If you purchased Primo Brands securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JYD
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the "Class Period"), of the important January 20, 2026 lead plaintiff deadline.
...keep reeding on newsfilecorp.com
AVTR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Avantor, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"), of the important December 29, 2025 lead plaintiff deadline. SO WHAT: If you purchased Avantor common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com